Olutasidenib
CAS 1423658-43-4 2 FDA-DMF suppliersSmall Molecule
Overview
Olutasidenib is a potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme involved in cellular metabolism which is often mutated in cancer. It is being investigated in the treatment of various cancers, including acute myeloid leukemia (AML) and cholangiocarcinoma.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Olutasidenib expires 12 Nov 2039 and exclusivity 1 Dec 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Oncology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.